**Supplementary Table 1. Unadjusted analysis of antiretroviral adherence and biomarkers of inflammation, coagulopathy and CD8+ T-cell activation six months after treatment initiation in study participants who achieved an HIV viral load of <400 copies/mL and <40 copies/mL.**

|  |  |  |
| --- | --- | --- |
|  | **Unadjusted Model for <400 copies/mLa** | **Unadjusted Model for <40 copies/mLa** |
| **Biomarker** | **Number ofParticipants** | **Percent reduction for each 10% increase in adherenceb** | **95% CI** | ***P*-value** | **Number of Participants** | **Percent reduction for each 10% increase in adherenceb**  | **95% CI** | ***P*-value** |
| **IL-6**  | 267 | -13.3 | (-19.3, -6.9) | *0.0001* | 128 | -9.7 | (-18.7, -0.3) | 0.057 |
| **D-dimer** | 271 | -9.4 | (-16.7, -1.4) | *0.023* | 132 | -9.0 | (-18.9, 2.0) | 0.105 |
| **KT ratio** | 270 | -3.1 | (-6.1, -0.04) | *0.047* | 129 | -2.2 | (-6.3, 2.1) | 0.317 |
| **sCD14** | 269 | -2.2 | (-4.3, -0.01) | *0.049* | 130 | -1.4 | (-4.3, 1.5) | 0.324 |
| **% HLA-DR+/CD38+ CD8+c** | 199 | -1.1 | (-2.2, 0.05) | 0.061 | 97 | -1.4 | (-3.1, 0.4) | 0.129 |
| **sCD163** | 269 | -2.4 | (-6, 1.2) | 0.190 | 130 | -6.3 | (-11.0, -1.4) | *0.013* |

aAdjusted only for baseline biomarkers. bPercent change from baseline after 6 months of therapy. cAbsolute decrease in proportion of CD8+ T-cells that co-express HLA-DR+/CD38+ (not percent decrease). IL-6: interleukin 6; KT: Kynurenine/tryptophan; sCD14: soluble CD14; sCD163: soluble CD163; 95% CI: 95% confidence interval.

**Supplementary Table 2. Sensitivity analysis of antiretroviral adherence and biomarkers of inflammation, coagulopathy and CD8+ T-cell activation six months after treatment initiation after removing highly influential points.**

|  |  |  |
| --- | --- | --- |
|  | **Unadjusted Modela** | **Full Modelb** |
| **Biomarker** | **Number ofParticipants Removed** | **Percent reduction for each 10% increase in adherencec** | **95% CI** | ***P*-value** | **Number of Participants Removed** | **Percent reduction for each 10% increase in adherencec**  | **95% CI** | ***P*-value** |
| **IL-6**  | 11 | -8.0 | (-16.8, 1.8) | 0.105 | 15 | -13.4 | (-22.2, -3.6) | *0.009* |
| **D-dimer** | 9 | -16.1 | (-27.8, -2.6) | *0.022* | 7 | -10.9 | (-18.9, -2.2) | *0.016* |
| **KT ratio** | 10 | -3.6 | (-10.4, 3.6) | 0.315 | 13 | -1.5 | (-5.6, 2.8) | 0.491 |
| **sCD14** | 11 | -1.9 | (-0.7, 0.3) | 0.460 | 14 | -2.6 | (-5.5, 0.4) | 0.086 |
| **% HLA-DR+/CD38+ CD8+d** | 7 | -1.9 | (-4.4, 0.6) | 0.132 | 7 | -1.5 | (-3.1, 0.22) | 0.089 |
| **sCD163** | 10 | -2.7 | (-9.6, 4.9) | 0.478 | 16 | -1.4 | (-5.8, 3.2) | 0.544 |

aAdjusted for baseline biomarkers. bFull model adjusted for baseline biomarkers, age, gender, and baseline values of CD4+ T cell count, HIV viral load, depression (Yes/No) and alcoholism (Yes/No). cPercent change from baseline after 6 months of therapy. dAbsolute decrease in proportion of CD8+ T-cells that co-express HLA-DR+/CD38+ (not percent decrease). IL-6: interleukin 6; KT: Kynurenine/tryptophan; sCD14: soluble CD14; sCD163: soluble CD163; 95% CI: 95% confidence interval.